nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ABCC1—Zoledronate—osteoporosis	0.135	0.212	CbGbCtD
Vemurafenib—ABCC1—Conjugated Estrogens—osteoporosis	0.075	0.118	CbGbCtD
Vemurafenib—ALB—Estropipate—osteoporosis	0.0732	0.115	CbGbCtD
Vemurafenib—ABCG2—Conjugated Estrogens—osteoporosis	0.0502	0.079	CbGbCtD
Vemurafenib—ABCG2—Estradiol—osteoporosis	0.0441	0.0694	CbGbCtD
Vemurafenib—CYP1A2—Estropipate—osteoporosis	0.0438	0.0689	CbGbCtD
Vemurafenib—ALB—Estradiol—osteoporosis	0.0304	0.0478	CbGbCtD
Vemurafenib—CYP3A4—Estropipate—osteoporosis	0.0229	0.0361	CbGbCtD
Vemurafenib—CYP3A4—Calcitriol—osteoporosis	0.0229	0.0361	CbGbCtD
Vemurafenib—CYP1A2—Conjugated Estrogens—osteoporosis	0.0207	0.0326	CbGbCtD
Vemurafenib—CYP2D6—Cholecalciferol—osteoporosis	0.0186	0.0292	CbGbCtD
Vemurafenib—CYP3A4—Ergocalciferol—osteoporosis	0.0183	0.0288	CbGbCtD
Vemurafenib—CYP1A2—Estradiol—osteoporosis	0.0182	0.0286	CbGbCtD
Vemurafenib—CYP3A4—Raloxifene—osteoporosis	0.0153	0.0241	CbGbCtD
Vemurafenib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0148	0.0233	CbGbCtD
Vemurafenib—CYP3A4—Cholecalciferol—osteoporosis	0.0118	0.0186	CbGbCtD
Vemurafenib—CYP3A4—Conjugated Estrogens—osteoporosis	0.0108	0.0171	CbGbCtD
Vemurafenib—CYP3A4—Estradiol—osteoporosis	0.00952	0.015	CbGbCtD
Vemurafenib—Musculoskeletal discomfort—Alendronate—osteoporosis	0.00035	0.00155	CcSEcCtD
Vemurafenib—Cardiac disorder—Zoledronate—osteoporosis	0.00035	0.00155	CcSEcCtD
Vemurafenib—Back pain—Pamidronate—osteoporosis	0.000347	0.00154	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Raloxifene—osteoporosis	0.000344	0.00152	CcSEcCtD
Vemurafenib—Erythema multiforme—Conjugated Estrogens—osteoporosis	0.000343	0.00152	CcSEcCtD
Vemurafenib—Angiopathy—Zoledronate—osteoporosis	0.000342	0.00151	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Ibandronate—osteoporosis	0.000341	0.00151	CcSEcCtD
Vemurafenib—Mediastinal disorder—Zoledronate—osteoporosis	0.00034	0.0015	CcSEcCtD
Vemurafenib—Eye disorder—Conjugated Estrogens—osteoporosis	0.000339	0.0015	CcSEcCtD
Vemurafenib—Chills—Zoledronate—osteoporosis	0.000338	0.0015	CcSEcCtD
Vemurafenib—Cough—Ethinyl Estradiol—osteoporosis	0.000338	0.0015	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Estropipate—osteoporosis	0.000337	0.00149	CcSEcCtD
Vemurafenib—Cardiac disorder—Conjugated Estrogens—osteoporosis	0.000337	0.00149	CcSEcCtD
Vemurafenib—Fatigue—Estropipate—osteoporosis	0.000336	0.00149	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Calcitriol—osteoporosis	0.000334	0.00148	CcSEcCtD
Vemurafenib—Constipation—Estropipate—osteoporosis	0.000334	0.00148	CcSEcCtD
Vemurafenib—Alopecia—Zoledronate—osteoporosis	0.000333	0.00147	CcSEcCtD
Vemurafenib—Hypersensitivity—Etidronic acid—osteoporosis	0.000332	0.00147	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Estradiol—osteoporosis	0.000331	0.00147	CcSEcCtD
Vemurafenib—Cough—Risedronate—osteoporosis	0.00033	0.00146	CcSEcCtD
Vemurafenib—Angiopathy—Conjugated Estrogens—osteoporosis	0.000329	0.00146	CcSEcCtD
Vemurafenib—Constipation—Alendronate—osteoporosis	0.000329	0.00146	CcSEcCtD
Vemurafenib—Weight decreased—Estradiol—osteoporosis	0.000328	0.00145	CcSEcCtD
Vemurafenib—Malnutrition—Zoledronate—osteoporosis	0.000328	0.00145	CcSEcCtD
Vemurafenib—Erythema—Zoledronate—osteoporosis	0.000328	0.00145	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000328	0.00145	CcSEcCtD
Vemurafenib—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.000327	0.00145	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000326	0.00144	CcSEcCtD
Vemurafenib—Decreased appetite—Ibandronate—osteoporosis	0.000325	0.00144	CcSEcCtD
Vemurafenib—Infestation NOS—Estradiol—osteoporosis	0.000323	0.00143	CcSEcCtD
Vemurafenib—Infestation—Estradiol—osteoporosis	0.000323	0.00143	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000323	0.00143	CcSEcCtD
Vemurafenib—Fatigue—Ibandronate—osteoporosis	0.000322	0.00143	CcSEcCtD
Vemurafenib—Myalgia—Risedronate—osteoporosis	0.000322	0.00142	CcSEcCtD
Vemurafenib—Arthralgia—Risedronate—osteoporosis	0.000322	0.00142	CcSEcCtD
Vemurafenib—Dysgeusia—Zoledronate—osteoporosis	0.000321	0.00142	CcSEcCtD
Vemurafenib—Alopecia—Conjugated Estrogens—osteoporosis	0.000321	0.00142	CcSEcCtD
Vemurafenib—Constipation—Ibandronate—osteoporosis	0.00032	0.00142	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000319	0.00141	CcSEcCtD
Vemurafenib—Pruritus—Etidronic acid—osteoporosis	0.000319	0.00141	CcSEcCtD
Vemurafenib—Decreased appetite—Calcitriol—osteoporosis	0.000318	0.00141	CcSEcCtD
Vemurafenib—Back pain—Zoledronate—osteoporosis	0.000317	0.00141	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Estradiol—osteoporosis	0.000317	0.0014	CcSEcCtD
Vemurafenib—Malnutrition—Conjugated Estrogens—osteoporosis	0.000316	0.0014	CcSEcCtD
Vemurafenib—Erythema—Conjugated Estrogens—osteoporosis	0.000316	0.0014	CcSEcCtD
Vemurafenib—Infection—Ethinyl Estradiol—osteoporosis	0.000314	0.00139	CcSEcCtD
Vemurafenib—Cough—Pamidronate—osteoporosis	0.000313	0.00139	CcSEcCtD
Vemurafenib—Constipation—Calcitriol—osteoporosis	0.000313	0.00139	CcSEcCtD
Vemurafenib—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.00031	0.00137	CcSEcCtD
Vemurafenib—Dysgeusia—Conjugated Estrogens—osteoporosis	0.000309	0.00137	CcSEcCtD
Vemurafenib—Diarrhoea—Etidronic acid—osteoporosis	0.000308	0.00137	CcSEcCtD
Vemurafenib—Body temperature increased—Estropipate—osteoporosis	0.000308	0.00137	CcSEcCtD
Vemurafenib—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000307	0.00136	CcSEcCtD
Vemurafenib—Infection—Risedronate—osteoporosis	0.000306	0.00136	CcSEcCtD
Vemurafenib—Arthralgia—Pamidronate—osteoporosis	0.000306	0.00135	CcSEcCtD
Vemurafenib—Myalgia—Pamidronate—osteoporosis	0.000306	0.00135	CcSEcCtD
Vemurafenib—Back pain—Conjugated Estrogens—osteoporosis	0.000305	0.00135	CcSEcCtD
Vemurafenib—Body temperature increased—Alendronate—osteoporosis	0.000304	0.00135	CcSEcCtD
Vemurafenib—Nervous system disorder—Risedronate—osteoporosis	0.000302	0.00134	CcSEcCtD
Vemurafenib—Skin disorder—Risedronate—osteoporosis	0.000299	0.00133	CcSEcCtD
Vemurafenib—Body temperature increased—Raloxifene—osteoporosis	0.000299	0.00132	CcSEcCtD
Vemurafenib—Body temperature increased—Ibandronate—osteoporosis	0.000296	0.00131	CcSEcCtD
Vemurafenib—Anaphylactic shock—Pamidronate—osteoporosis	0.000293	0.0013	CcSEcCtD
Vemurafenib—Infection—Pamidronate—osteoporosis	0.000291	0.00129	CcSEcCtD
Vemurafenib—Body temperature increased—Calcitriol—osteoporosis	0.000289	0.00128	CcSEcCtD
Vemurafenib—Hypersensitivity—Estropipate—osteoporosis	0.000287	0.00127	CcSEcCtD
Vemurafenib—Nervous system disorder—Pamidronate—osteoporosis	0.000287	0.00127	CcSEcCtD
Vemurafenib—Vomiting—Etidronic acid—osteoporosis	0.000287	0.00127	CcSEcCtD
Vemurafenib—Cough—Zoledronate—osteoporosis	0.000286	0.00127	CcSEcCtD
Vemurafenib—Oedema peripheral—Estradiol—osteoporosis	0.000286	0.00127	CcSEcCtD
Vemurafenib—Connective tissue disorder—Estradiol—osteoporosis	0.000285	0.00126	CcSEcCtD
Vemurafenib—Rash—Etidronic acid—osteoporosis	0.000284	0.00126	CcSEcCtD
Vemurafenib—Dermatitis—Etidronic acid—osteoporosis	0.000284	0.00126	CcSEcCtD
Vemurafenib—Hypersensitivity—Alendronate—osteoporosis	0.000283	0.00125	CcSEcCtD
Vemurafenib—Headache—Etidronic acid—osteoporosis	0.000282	0.00125	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000281	0.00124	CcSEcCtD
Vemurafenib—Asthenia—Estropipate—osteoporosis	0.00028	0.00124	CcSEcCtD
Vemurafenib—Myalgia—Zoledronate—osteoporosis	0.000279	0.00124	CcSEcCtD
Vemurafenib—Arthralgia—Zoledronate—osteoporosis	0.000279	0.00124	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000277	0.00123	CcSEcCtD
Vemurafenib—Pruritus—Estropipate—osteoporosis	0.000276	0.00122	CcSEcCtD
Vemurafenib—Asthenia—Alendronate—osteoporosis	0.000276	0.00122	CcSEcCtD
Vemurafenib—Hypersensitivity—Ibandronate—osteoporosis	0.000276	0.00122	CcSEcCtD
Vemurafenib—Cough—Conjugated Estrogens—osteoporosis	0.000276	0.00122	CcSEcCtD
Vemurafenib—Erythema multiforme—Estradiol—osteoporosis	0.000275	0.00122	CcSEcCtD
Vemurafenib—Hypotension—Pamidronate—osteoporosis	0.000274	0.00121	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000273	0.00121	CcSEcCtD
Vemurafenib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000273	0.00121	CcSEcCtD
Vemurafenib—Pruritus—Alendronate—osteoporosis	0.000272	0.0012	CcSEcCtD
Vemurafenib—Eye disorder—Estradiol—osteoporosis	0.000271	0.0012	CcSEcCtD
Vemurafenib—Constipation—Ethinyl Estradiol—osteoporosis	0.00027	0.0012	CcSEcCtD
Vemurafenib—Hypersensitivity—Calcitriol—osteoporosis	0.00027	0.00119	CcSEcCtD
Vemurafenib—Cardiac disorder—Estradiol—osteoporosis	0.000269	0.00119	CcSEcCtD
Vemurafenib—Arthralgia—Conjugated Estrogens—osteoporosis	0.000269	0.00119	CcSEcCtD
Vemurafenib—Myalgia—Conjugated Estrogens—osteoporosis	0.000269	0.00119	CcSEcCtD
Vemurafenib—Asthenia—Ibandronate—osteoporosis	0.000268	0.00119	CcSEcCtD
Vemurafenib—Nausea—Etidronic acid—osteoporosis	0.000268	0.00119	CcSEcCtD
Vemurafenib—Anaphylactic shock—Zoledronate—osteoporosis	0.000268	0.00119	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000267	0.00118	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000267	0.00118	CcSEcCtD
Vemurafenib—Diarrhoea—Estropipate—osteoporosis	0.000267	0.00118	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Risedronate—osteoporosis	0.000266	0.00118	CcSEcCtD
Vemurafenib—Infection—Zoledronate—osteoporosis	0.000266	0.00118	CcSEcCtD
Vemurafenib—Fatigue—Risedronate—osteoporosis	0.000266	0.00118	CcSEcCtD
Vemurafenib—Pruritus—Ibandronate—osteoporosis	0.000265	0.00117	CcSEcCtD
Vemurafenib—Constipation—Risedronate—osteoporosis	0.000264	0.00117	CcSEcCtD
Vemurafenib—Angiopathy—Estradiol—osteoporosis	0.000263	0.00117	CcSEcCtD
Vemurafenib—Diarrhoea—Alendronate—osteoporosis	0.000263	0.00116	CcSEcCtD
Vemurafenib—Asthenia—Calcitriol—osteoporosis	0.000263	0.00116	CcSEcCtD
Vemurafenib—Nervous system disorder—Zoledronate—osteoporosis	0.000263	0.00116	CcSEcCtD
Vemurafenib—Mediastinal disorder—Estradiol—osteoporosis	0.000262	0.00116	CcSEcCtD
Vemurafenib—Chills—Estradiol—osteoporosis	0.000261	0.00115	CcSEcCtD
Vemurafenib—Skin disorder—Zoledronate—osteoporosis	0.00026	0.00115	CcSEcCtD
Vemurafenib—Pruritus—Calcitriol—osteoporosis	0.000259	0.00115	CcSEcCtD
Vemurafenib—Diarrhoea—Raloxifene—osteoporosis	0.000259	0.00115	CcSEcCtD
Vemurafenib—Dizziness—Estropipate—osteoporosis	0.000258	0.00114	CcSEcCtD
Vemurafenib—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000258	0.00114	CcSEcCtD
Vemurafenib—Alopecia—Estradiol—osteoporosis	0.000257	0.00114	CcSEcCtD
Vemurafenib—Infection—Conjugated Estrogens—osteoporosis	0.000256	0.00113	CcSEcCtD
Vemurafenib—Diarrhoea—Ibandronate—osteoporosis	0.000256	0.00113	CcSEcCtD
Vemurafenib—Decreased appetite—Pamidronate—osteoporosis	0.000255	0.00113	CcSEcCtD
Vemurafenib—Dizziness—Alendronate—osteoporosis	0.000254	0.00113	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000253	0.00112	CcSEcCtD
Vemurafenib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000253	0.00112	CcSEcCtD
Vemurafenib—Erythema—Estradiol—osteoporosis	0.000253	0.00112	CcSEcCtD
Vemurafenib—Malnutrition—Estradiol—osteoporosis	0.000253	0.00112	CcSEcCtD
Vemurafenib—Fatigue—Pamidronate—osteoporosis	0.000253	0.00112	CcSEcCtD
Vemurafenib—Constipation—Pamidronate—osteoporosis	0.000251	0.00111	CcSEcCtD
Vemurafenib—Diarrhoea—Calcitriol—osteoporosis	0.000251	0.00111	CcSEcCtD
Vemurafenib—Skin disorder—Conjugated Estrogens—osteoporosis	0.00025	0.00111	CcSEcCtD
Vemurafenib—Hypotension—Zoledronate—osteoporosis	0.00025	0.00111	CcSEcCtD
Vemurafenib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.00025	0.00111	CcSEcCtD
Vemurafenib—Dizziness—Raloxifene—osteoporosis	0.00025	0.00111	CcSEcCtD
Vemurafenib—Vomiting—Estropipate—osteoporosis	0.000248	0.0011	CcSEcCtD
Vemurafenib—Dysgeusia—Estradiol—osteoporosis	0.000248	0.0011	CcSEcCtD
Vemurafenib—Dizziness—Ibandronate—osteoporosis	0.000247	0.0011	CcSEcCtD
Vemurafenib—Rash—Estropipate—osteoporosis	0.000246	0.00109	CcSEcCtD
Vemurafenib—Dermatitis—Estropipate—osteoporosis	0.000246	0.00109	CcSEcCtD
Vemurafenib—Back pain—Estradiol—osteoporosis	0.000244	0.00108	CcSEcCtD
Vemurafenib—Headache—Estropipate—osteoporosis	0.000244	0.00108	CcSEcCtD
Vemurafenib—Vomiting—Alendronate—osteoporosis	0.000244	0.00108	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000244	0.00108	CcSEcCtD
Vemurafenib—Body temperature increased—Risedronate—osteoporosis	0.000244	0.00108	CcSEcCtD
Vemurafenib—Rash—Alendronate—osteoporosis	0.000242	0.00107	CcSEcCtD
Vemurafenib—Dermatitis—Alendronate—osteoporosis	0.000242	0.00107	CcSEcCtD
Vemurafenib—Hypotension—Conjugated Estrogens—osteoporosis	0.000241	0.00107	CcSEcCtD
Vemurafenib—Headache—Alendronate—osteoporosis	0.000241	0.00107	CcSEcCtD
Vemurafenib—Vomiting—Raloxifene—osteoporosis	0.00024	0.00106	CcSEcCtD
Vemurafenib—Rash—Raloxifene—osteoporosis	0.000238	0.00106	CcSEcCtD
Vemurafenib—Dermatitis—Raloxifene—osteoporosis	0.000238	0.00105	CcSEcCtD
Vemurafenib—Vomiting—Ibandronate—osteoporosis	0.000238	0.00105	CcSEcCtD
Vemurafenib—Headache—Raloxifene—osteoporosis	0.000237	0.00105	CcSEcCtD
Vemurafenib—Rash—Ibandronate—osteoporosis	0.000236	0.00104	CcSEcCtD
Vemurafenib—Dermatitis—Ibandronate—osteoporosis	0.000236	0.00104	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000235	0.00104	CcSEcCtD
Vemurafenib—Headache—Ibandronate—osteoporosis	0.000234	0.00104	CcSEcCtD
Vemurafenib—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000233	0.00103	CcSEcCtD
Vemurafenib—Vomiting—Calcitriol—osteoporosis	0.000233	0.00103	CcSEcCtD
Vemurafenib—Decreased appetite—Zoledronate—osteoporosis	0.000233	0.00103	CcSEcCtD
Vemurafenib—Nausea—Estropipate—osteoporosis	0.000232	0.00103	CcSEcCtD
Vemurafenib—Body temperature increased—Pamidronate—osteoporosis	0.000232	0.00103	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000231	0.00102	CcSEcCtD
Vemurafenib—Rash—Calcitriol—osteoporosis	0.000231	0.00102	CcSEcCtD
Vemurafenib—Fatigue—Zoledronate—osteoporosis	0.000231	0.00102	CcSEcCtD
Vemurafenib—Dermatitis—Calcitriol—osteoporosis	0.000231	0.00102	CcSEcCtD
Vemurafenib—Headache—Calcitriol—osteoporosis	0.000229	0.00102	CcSEcCtD
Vemurafenib—Constipation—Zoledronate—osteoporosis	0.000229	0.00101	CcSEcCtD
Vemurafenib—Nausea—Alendronate—osteoporosis	0.000228	0.00101	CcSEcCtD
Vemurafenib—Hypersensitivity—Risedronate—osteoporosis	0.000227	0.00101	CcSEcCtD
Vemurafenib—Asthenia—Ethinyl Estradiol—osteoporosis	0.000227	0.001	CcSEcCtD
Vemurafenib—Nausea—Raloxifene—osteoporosis	0.000224	0.000994	CcSEcCtD
Vemurafenib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000224	0.000992	CcSEcCtD
Vemurafenib—Pruritus—Ethinyl Estradiol—osteoporosis	0.000224	0.000991	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000223	0.000986	CcSEcCtD
Vemurafenib—Fatigue—Conjugated Estrogens—osteoporosis	0.000222	0.000984	CcSEcCtD
Vemurafenib—Nausea—Ibandronate—osteoporosis	0.000222	0.000984	CcSEcCtD
Vemurafenib—Asthenia—Risedronate—osteoporosis	0.000221	0.00098	CcSEcCtD
Vemurafenib—Cough—Estradiol—osteoporosis	0.000221	0.000977	CcSEcCtD
Vemurafenib—Constipation—Conjugated Estrogens—osteoporosis	0.00022	0.000976	CcSEcCtD
Vemurafenib—Pruritus—Risedronate—osteoporosis	0.000218	0.000966	CcSEcCtD
Vemurafenib—Nausea—Calcitriol—osteoporosis	0.000217	0.000963	CcSEcCtD
Vemurafenib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000216	0.000958	CcSEcCtD
Vemurafenib—Hypersensitivity—Pamidronate—osteoporosis	0.000216	0.000956	CcSEcCtD
Vemurafenib—Arthralgia—Estradiol—osteoporosis	0.000215	0.000953	CcSEcCtD
Vemurafenib—Myalgia—Estradiol—osteoporosis	0.000215	0.000953	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000214	0.000946	CcSEcCtD
Vemurafenib—Body temperature increased—Zoledronate—osteoporosis	0.000212	0.000937	CcSEcCtD
Vemurafenib—Diarrhoea—Risedronate—osteoporosis	0.000211	0.000934	CcSEcCtD
Vemurafenib—Asthenia—Pamidronate—osteoporosis	0.00021	0.000931	CcSEcCtD
Vemurafenib—Dizziness—Ethinyl Estradiol—osteoporosis	0.000209	0.000926	CcSEcCtD
Vemurafenib—Pruritus—Pamidronate—osteoporosis	0.000207	0.000918	CcSEcCtD
Vemurafenib—Anaphylactic shock—Estradiol—osteoporosis	0.000206	0.000914	CcSEcCtD
Vemurafenib—Infection—Estradiol—osteoporosis	0.000205	0.000908	CcSEcCtD
Vemurafenib—Dizziness—Risedronate—osteoporosis	0.000204	0.000903	CcSEcCtD
Vemurafenib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000204	0.000902	CcSEcCtD
Vemurafenib—Nervous system disorder—Estradiol—osteoporosis	0.000202	0.000896	CcSEcCtD
Vemurafenib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000201	0.00089	CcSEcCtD
Vemurafenib—Diarrhoea—Pamidronate—osteoporosis	0.000201	0.000888	CcSEcCtD
Vemurafenib—Skin disorder—Estradiol—osteoporosis	0.0002	0.000887	CcSEcCtD
Vemurafenib—Rash—Ethinyl Estradiol—osteoporosis	0.000199	0.000883	CcSEcCtD
Vemurafenib—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000199	0.000882	CcSEcCtD
Vemurafenib—Headache—Ethinyl Estradiol—osteoporosis	0.000198	0.000877	CcSEcCtD
Vemurafenib—Hypersensitivity—Zoledronate—osteoporosis	0.000197	0.000873	CcSEcCtD
Vemurafenib—Vomiting—Risedronate—osteoporosis	0.000196	0.000868	CcSEcCtD
Vemurafenib—Rash—Risedronate—osteoporosis	0.000194	0.000861	CcSEcCtD
Vemurafenib—Dermatitis—Risedronate—osteoporosis	0.000194	0.00086	CcSEcCtD
Vemurafenib—Dizziness—Pamidronate—osteoporosis	0.000194	0.000858	CcSEcCtD
Vemurafenib—Headache—Risedronate—osteoporosis	0.000193	0.000855	CcSEcCtD
Vemurafenib—Asthenia—Zoledronate—osteoporosis	0.000192	0.000851	CcSEcCtD
Vemurafenib—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.00019	0.000841	CcSEcCtD
Vemurafenib—Pruritus—Zoledronate—osteoporosis	0.000189	0.000839	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000188	0.000832	CcSEcCtD
Vemurafenib—Nausea—Ethinyl Estradiol—osteoporosis	0.000188	0.000832	CcSEcCtD
Vemurafenib—Vomiting—Pamidronate—osteoporosis	0.000186	0.000825	CcSEcCtD
Vemurafenib—Asthenia—Conjugated Estrogens—osteoporosis	0.000185	0.000819	CcSEcCtD
Vemurafenib—Rash—Pamidronate—osteoporosis	0.000185	0.000818	CcSEcCtD
Vemurafenib—Dermatitis—Pamidronate—osteoporosis	0.000185	0.000818	CcSEcCtD
Vemurafenib—Headache—Pamidronate—osteoporosis	0.000184	0.000813	CcSEcCtD
Vemurafenib—Diarrhoea—Zoledronate—osteoporosis	0.000183	0.000811	CcSEcCtD
Vemurafenib—Nausea—Risedronate—osteoporosis	0.000183	0.000811	CcSEcCtD
Vemurafenib—Pruritus—Conjugated Estrogens—osteoporosis	0.000182	0.000808	CcSEcCtD
Vemurafenib—Decreased appetite—Estradiol—osteoporosis	0.000179	0.000794	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Estradiol—osteoporosis	0.000178	0.000789	CcSEcCtD
Vemurafenib—Fatigue—Estradiol—osteoporosis	0.000178	0.000788	CcSEcCtD
Vemurafenib—Dizziness—Zoledronate—osteoporosis	0.000177	0.000784	CcSEcCtD
Vemurafenib—Constipation—Estradiol—osteoporosis	0.000176	0.000781	CcSEcCtD
Vemurafenib—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000176	0.000781	CcSEcCtD
Vemurafenib—Nausea—Pamidronate—osteoporosis	0.000174	0.000771	CcSEcCtD
Vemurafenib—Dizziness—Conjugated Estrogens—osteoporosis	0.00017	0.000755	CcSEcCtD
Vemurafenib—Vomiting—Zoledronate—osteoporosis	0.00017	0.000754	CcSEcCtD
Vemurafenib—Rash—Zoledronate—osteoporosis	0.000169	0.000748	CcSEcCtD
Vemurafenib—Dermatitis—Zoledronate—osteoporosis	0.000169	0.000747	CcSEcCtD
Vemurafenib—Headache—Zoledronate—osteoporosis	0.000168	0.000743	CcSEcCtD
Vemurafenib—Vomiting—Conjugated Estrogens—osteoporosis	0.000164	0.000726	CcSEcCtD
Vemurafenib—Body temperature increased—Estradiol—osteoporosis	0.000163	0.000722	CcSEcCtD
Vemurafenib—Rash—Conjugated Estrogens—osteoporosis	0.000163	0.00072	CcSEcCtD
Vemurafenib—Dermatitis—Conjugated Estrogens—osteoporosis	0.000162	0.000719	CcSEcCtD
Vemurafenib—Headache—Conjugated Estrogens—osteoporosis	0.000161	0.000715	CcSEcCtD
Vemurafenib—Nausea—Zoledronate—osteoporosis	0.000159	0.000704	CcSEcCtD
Vemurafenib—Nausea—Conjugated Estrogens—osteoporosis	0.000153	0.000678	CcSEcCtD
Vemurafenib—Hypersensitivity—Estradiol—osteoporosis	0.000152	0.000673	CcSEcCtD
Vemurafenib—Asthenia—Estradiol—osteoporosis	0.000148	0.000656	CcSEcCtD
Vemurafenib—Pruritus—Estradiol—osteoporosis	0.000146	0.000646	CcSEcCtD
Vemurafenib—Diarrhoea—Estradiol—osteoporosis	0.000141	0.000625	CcSEcCtD
Vemurafenib—Dizziness—Estradiol—osteoporosis	0.000136	0.000604	CcSEcCtD
Vemurafenib—Vomiting—Estradiol—osteoporosis	0.000131	0.000581	CcSEcCtD
Vemurafenib—Rash—Estradiol—osteoporosis	0.00013	0.000576	CcSEcCtD
Vemurafenib—Dermatitis—Estradiol—osteoporosis	0.00013	0.000576	CcSEcCtD
Vemurafenib—Headache—Estradiol—osteoporosis	0.000129	0.000572	CcSEcCtD
Vemurafenib—Nausea—Estradiol—osteoporosis	0.000123	0.000543	CcSEcCtD
Vemurafenib—RAF1—Innate Immune System—IRS2—osteoporosis	3.67e-05	0.000264	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—IL6—osteoporosis	3.67e-05	0.000264	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTHLH—osteoporosis	3.65e-05	0.000262	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—BMP2—osteoporosis	3.65e-05	0.000262	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GAPDH—osteoporosis	3.64e-05	0.000262	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TLN1—osteoporosis	3.63e-05	0.000261	CbGpPWpGaD
Vemurafenib—CYP2D6—Biological oxidations—POMC—osteoporosis	3.61e-05	0.00026	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PNP—osteoporosis	3.58e-05	0.000257	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ATIC—osteoporosis	3.58e-05	0.000257	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FGB—osteoporosis	3.57e-05	0.000257	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—RAP1A—osteoporosis	3.55e-05	0.000255	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—IRS2—osteoporosis	3.52e-05	0.000254	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.52e-05	0.000253	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—TPI1—osteoporosis	3.47e-05	0.00025	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ENO1—osteoporosis	3.45e-05	0.000249	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—osteoporosis	3.45e-05	0.000248	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—IL6—osteoporosis	3.45e-05	0.000248	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—IL6—osteoporosis	3.45e-05	0.000248	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PSMA5—osteoporosis	3.44e-05	0.000248	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PSMA2—osteoporosis	3.44e-05	0.000248	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—IGF1—osteoporosis	3.44e-05	0.000248	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ENO1—osteoporosis	3.42e-05	0.000246	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—IL6—osteoporosis	3.42e-05	0.000246	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6R—osteoporosis	3.41e-05	0.000245	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—FDPS—osteoporosis	3.4e-05	0.000245	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PKM—osteoporosis	3.4e-05	0.000245	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PSMA2—osteoporosis	3.4e-05	0.000245	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PSMA5—osteoporosis	3.4e-05	0.000245	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—IL6—osteoporosis	3.4e-05	0.000245	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—IL6—osteoporosis	3.39e-05	0.000244	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—IL6—osteoporosis	3.37e-05	0.000243	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PSMA2—osteoporosis	3.37e-05	0.000243	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PSMA5—osteoporosis	3.37e-05	0.000243	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—IGF1—osteoporosis	3.3e-05	0.000237	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—P4HB—osteoporosis	3.26e-05	0.000235	CbGpPWpGaD
Vemurafenib—BRAF—Disease—ADCY5—osteoporosis	3.26e-05	0.000235	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IL6—osteoporosis	3.25e-05	0.000234	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PGLS—osteoporosis	3.23e-05	0.000232	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GPD2—osteoporosis	3.23e-05	0.000232	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CALCA—osteoporosis	3.21e-05	0.000231	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GAPDH—osteoporosis	3.2e-05	0.000231	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IRS1—osteoporosis	3.2e-05	0.000231	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CALCA—osteoporosis	3.17e-05	0.000228	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	3.16e-05	0.000228	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CALCA—osteoporosis	3.14e-05	0.000226	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—P4HB—osteoporosis	3.13e-05	0.000225	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—RAP1A—osteoporosis	3.12e-05	0.000225	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KL—osteoporosis	3.12e-05	0.000225	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.09e-05	0.000223	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—IRS1—osteoporosis	3.08e-05	0.000221	CbGpPWpGaD
Vemurafenib—CYP1A2—Biological oxidations—POMC—osteoporosis	3.06e-05	0.00022	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	3.06e-05	0.00022	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTH—osteoporosis	3.04e-05	0.000219	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—OXCT1—osteoporosis	3.04e-05	0.000219	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CA2—osteoporosis	3.04e-05	0.000219	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6R—osteoporosis	3.01e-05	0.000217	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MTHFR—osteoporosis	3e-05	0.000216	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RAP1A—osteoporosis	2.99e-05	0.000215	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CNR2—osteoporosis	2.97e-05	0.000214	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MGLL—osteoporosis	2.96e-05	0.000213	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	2.95e-05	0.000213	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ATIC—osteoporosis	2.95e-05	0.000213	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PNP—osteoporosis	2.95e-05	0.000213	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NFATC1—osteoporosis	2.92e-05	0.00021	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KL—osteoporosis	2.91e-05	0.00021	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—DKK1—osteoporosis	2.89e-05	0.000208	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PKM—osteoporosis	2.88e-05	0.000208	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—FDPS—osteoporosis	2.88e-05	0.000208	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KL—osteoporosis	2.88e-05	0.000207	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ENO1—osteoporosis	2.87e-05	0.000206	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KL—osteoporosis	2.85e-05	0.000205	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IRS2—osteoporosis	2.85e-05	0.000205	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PSMA2—osteoporosis	2.82e-05	0.000203	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PSMA5—osteoporosis	2.82e-05	0.000203	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.79e-05	0.000201	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—WNT1—osteoporosis	2.79e-05	0.000201	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PGLS—osteoporosis	2.73e-05	0.000197	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GPD2—osteoporosis	2.73e-05	0.000197	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGA—osteoporosis	2.71e-05	0.000195	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—ADCY5—osteoporosis	2.67e-05	0.000192	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ENO1—osteoporosis	2.52e-05	0.000182	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTHLH—osteoporosis	2.52e-05	0.000182	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—BMP2—osteoporosis	2.52e-05	0.000182	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—IDH2—osteoporosis	2.52e-05	0.000181	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CA2—osteoporosis	2.51e-05	0.000181	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—OXCT1—osteoporosis	2.51e-05	0.000181	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ATIC—osteoporosis	2.5e-05	0.00018	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PNP—osteoporosis	2.5e-05	0.00018	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IRS1—osteoporosis	2.49e-05	0.000179	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PSMA2—osteoporosis	2.49e-05	0.000179	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PSMA5—osteoporosis	2.49e-05	0.000179	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGB—osteoporosis	2.47e-05	0.000178	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AGER—osteoporosis	2.45e-05	0.000176	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MGLL—osteoporosis	2.45e-05	0.000176	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ADCY5—osteoporosis	2.44e-05	0.000176	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL6—osteoporosis	2.39e-05	0.000172	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PSMA2—osteoporosis	2.38e-05	0.000172	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PSMA5—osteoporosis	2.38e-05	0.000172	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP27A1—osteoporosis	2.37e-05	0.000171	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—POMC—osteoporosis	2.36e-05	0.00017	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—IL6—osteoporosis	2.35e-05	0.000169	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6R—osteoporosis	2.34e-05	0.000168	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ACP5—osteoporosis	2.3e-05	0.000166	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CYP19A1—osteoporosis	2.29e-05	0.000165	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ADCY5—osteoporosis	2.28e-05	0.000164	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.27e-05	0.000164	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ADCY5—osteoporosis	2.26e-05	0.000162	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ADCY5—osteoporosis	2.24e-05	0.000161	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—FDPS—osteoporosis	2.23e-05	0.00016	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PKM—osteoporosis	2.23e-05	0.00016	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CALCA—osteoporosis	2.22e-05	0.00016	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SPP1—osteoporosis	2.21e-05	0.000159	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—ADCY5—osteoporosis	2.17e-05	0.000156	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TPI1—osteoporosis	2.14e-05	0.000154	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IRS2—osteoporosis	2.14e-05	0.000154	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—IL6—osteoporosis	2.13e-05	0.000153	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—OXCT1—osteoporosis	2.13e-05	0.000153	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CA2—osteoporosis	2.13e-05	0.000153	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPD2—osteoporosis	2.11e-05	0.000152	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PGLS—osteoporosis	2.11e-05	0.000152	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—IDH2—osteoporosis	2.08e-05	0.00015	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MTHFR—osteoporosis	2.07e-05	0.000149	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MGLL—osteoporosis	2.07e-05	0.000149	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	2.06e-05	0.000149	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MTHFR—osteoporosis	2.06e-05	0.000148	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CYP19A1—osteoporosis	2.02e-05	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KL—osteoporosis	2.02e-05	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TGFB1—osteoporosis	2.01e-05	0.000145	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—P4HB—osteoporosis	2.01e-05	0.000145	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IRS2—osteoporosis	2e-05	0.000144	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GAPDH—osteoporosis	1.98e-05	0.000142	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TGFB1—osteoporosis	1.98e-05	0.000142	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IRS2—osteoporosis	1.97e-05	0.000142	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—POMC—osteoporosis	1.97e-05	0.000142	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IRS2—osteoporosis	1.96e-05	0.000141	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP27A1—osteoporosis	1.96e-05	0.000141	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—LEP—osteoporosis	1.95e-05	0.000141	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.95e-05	0.000141	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ATIC—osteoporosis	1.93e-05	0.000139	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PNP—osteoporosis	1.93e-05	0.000139	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—RAP1A—osteoporosis	1.93e-05	0.000139	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6R—osteoporosis	1.92e-05	0.000138	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ACP5—osteoporosis	1.9e-05	0.000137	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—osteoporosis	1.88e-05	0.000135	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ADCY5—osteoporosis	1.87e-05	0.000135	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ESR1—osteoporosis	1.87e-05	0.000134	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GPX1—osteoporosis	1.87e-05	0.000134	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IRS1—osteoporosis	1.87e-05	0.000134	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IGF1—osteoporosis	1.77e-05	0.000128	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TPI1—osteoporosis	1.77e-05	0.000127	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—IDH2—osteoporosis	1.76e-05	0.000127	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6R—osteoporosis	1.75e-05	0.000126	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IRS1—osteoporosis	1.74e-05	0.000126	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IRS1—osteoporosis	1.72e-05	0.000124	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—MTHFR—osteoporosis	1.72e-05	0.000124	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IRS1—osteoporosis	1.71e-05	0.000123	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—POMC—osteoporosis	1.68e-05	0.000121	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.68e-05	0.000121	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—P4HB—osteoporosis	1.66e-05	0.00012	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP27A1—osteoporosis	1.66e-05	0.000119	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ADCY5—osteoporosis	1.65e-05	0.000119	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GPX1—osteoporosis	1.64e-05	0.000118	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CA2—osteoporosis	1.64e-05	0.000118	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—OXCT1—osteoporosis	1.64e-05	0.000118	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6R—osteoporosis	1.64e-05	0.000118	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GAPDH—osteoporosis	1.63e-05	0.000118	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6R—osteoporosis	1.62e-05	0.000117	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IGF1—osteoporosis	1.62e-05	0.000116	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ACP5—osteoporosis	1.61e-05	0.000116	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6R—osteoporosis	1.6e-05	0.000115	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MGLL—osteoporosis	1.6e-05	0.000115	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.59e-05	0.000115	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—RAP1A—osteoporosis	1.59e-05	0.000114	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ADCY5—osteoporosis	1.58e-05	0.000114	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ENO1—osteoporosis	1.56e-05	0.000112	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PSMA2—osteoporosis	1.53e-05	0.00011	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PSMA5—osteoporosis	1.53e-05	0.00011	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SPP1—osteoporosis	1.53e-05	0.00011	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6—osteoporosis	1.52e-05	0.000109	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—MTHFR—osteoporosis	1.52e-05	0.000109	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TPI1—osteoporosis	1.5e-05	0.000108	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—P4HB—osteoporosis	1.41e-05	0.000101	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MYC—osteoporosis	1.39e-05	9.98e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFB1—osteoporosis	1.38e-05	9.95e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GAPDH—osteoporosis	1.38e-05	9.95e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IRS2—osteoporosis	1.38e-05	9.95e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—POMC—osteoporosis	1.38e-05	9.91e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—IDH2—osteoporosis	1.36e-05	9.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—LEP—osteoporosis	1.35e-05	9.74e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—RAP1A—osteoporosis	1.35e-05	9.7e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—osteoporosis	1.34e-05	9.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1B—osteoporosis	1.33e-05	9.6e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ESR1—osteoporosis	1.29e-05	9.3e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ENO1—osteoporosis	1.28e-05	9.25e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.28e-05	9.21e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PSMA2—osteoporosis	1.27e-05	9.12e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PSMA5—osteoporosis	1.27e-05	9.12e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP19A1—osteoporosis	1.24e-05	8.96e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ACP5—osteoporosis	1.24e-05	8.95e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—POMC—osteoporosis	1.21e-05	8.72e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IRS1—osteoporosis	1.21e-05	8.69e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.17e-05	8.46e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—POMC—osteoporosis	1.16e-05	8.36e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TPI1—osteoporosis	1.16e-05	8.32e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6R—osteoporosis	1.13e-05	8.16e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1—osteoporosis	1.12e-05	8.05e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ENO1—osteoporosis	1.09e-05	7.84e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—P4HB—osteoporosis	1.09e-05	7.83e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PSMA2—osteoporosis	1.07e-05	7.72e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PSMA5—osteoporosis	1.07e-05	7.72e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GAPDH—osteoporosis	1.07e-05	7.68e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—osteoporosis	1.06e-05	7.66e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—osteoporosis	1.04e-05	7.5e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—RAP1A—osteoporosis	1.04e-05	7.48e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP19A1—osteoporosis	1.03e-05	7.4e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ADCY5—osteoporosis	1.02e-05	7.32e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GPX1—osteoporosis	1.01e-05	7.29e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—osteoporosis	9.71e-06	6.99e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—osteoporosis	9.68e-06	6.97e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—osteoporosis	9.59e-06	6.9e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—osteoporosis	9.57e-06	6.89e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—osteoporosis	9.51e-06	6.84e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—osteoporosis	9.48e-06	6.83e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—osteoporosis	9.35e-06	6.73e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP19A1—osteoporosis	8.7e-06	6.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—osteoporosis	8.54e-06	6.15e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ENO1—osteoporosis	8.4e-06	6.05e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ADCY5—osteoporosis	8.39e-06	6.04e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GPX1—osteoporosis	8.36e-06	6.02e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PSMA2—osteoporosis	8.28e-06	5.96e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PSMA5—osteoporosis	8.28e-06	5.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—osteoporosis	7.81e-06	5.62e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—osteoporosis	7.72e-06	5.56e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—POMC—osteoporosis	7.48e-06	5.38e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—osteoporosis	7.3e-06	5.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—osteoporosis	7.21e-06	5.19e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—osteoporosis	7.15e-06	5.14e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ADCY5—osteoporosis	7.11e-06	5.12e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GPX1—osteoporosis	7.09e-06	5.1e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP19A1—osteoporosis	6.72e-06	4.84e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—osteoporosis	6.72e-06	4.83e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—osteoporosis	6.7e-06	4.82e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—osteoporosis	6.54e-06	4.71e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—POMC—osteoporosis	6.17e-06	4.44e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ADCY5—osteoporosis	5.49e-06	3.95e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPX1—osteoporosis	5.47e-06	3.94e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—POMC—osteoporosis	5.23e-06	3.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—osteoporosis	5.05e-06	3.63e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—osteoporosis	5.05e-06	3.63e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—POMC—osteoporosis	4.04e-06	2.91e-05	CbGpPWpGaD
